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Twenty-six patients presenting with 28 instances of mas•
sive acute thrombotic obstruction of a prosthetic valve 
(16 mitral, 12 aortic) were treated with fibrinolytic agents. 
In 15 cases the patient presented with acute pulmonary 
edema and low cardiac output, in 10 with congestive 
heart failure and embolism and in 3 with peripheral 
embolism only. The diagnosis of thrombotic obstruction 
was made by echocardiography or cineradiography, in 
patients in whom the disc was immobile or barely mov•
ing; cineangiography was necessary in only four pa•
tients. The fibrinolytic agents administered were strep•
tokinase, 2,000,000 U for 10 hours (14 cases), urokinase, 
4,500 U/kg per h for 12 hours (7 cases), or the two agents 
successively (7 cases). Fibrinolysis was entirely successful 
in 19 patients: 18 are alive and well without surgical 
intervention after follow-up of 6 to 64 months and 1 
patient had surgical revision after fibrinolysis. In two 
Despite improvements in the design of prosthetic cardiac 
valves, arterial thromboembolic complications after valve 
replacement remain a frequent cause of illness and mortality, 
often as a result of defects in anticoagulant therapy. An even 
more life-threatening event is massive thrombosis of the 
valve itself, which must be detected and treated promptly. 
Echocardiographic and cineradiographic studies of tilting 
disc valves are often helpful for early diagnosis. The re•
ported incidence of thrombosis ranges from 0.5 to 5% (1-4), 
with a mortality rate of about 40% before or In spite of 
surgical treatment. Thrombectomy and debridement of the 
disc valve are the treatments usually favored in such cases, 
especially for aortic valves (5,6). However. many cata•
strophically ill patients die suddenly before an operation can 
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patients, fibrinolytic treatment was apparently success•
ful but obstruction recurred 4 and 19 months later, re•
spectively, and the patients were again treated by fibri•
nolysis. In two patients complete failure of fibrinolytic 
treatment led to emergency surgery, and in three pa•
tients improvement was incomplete and death occurred 
shortly after treatment. 
No hemorrhagic complications were observed, but 
there were five cases of embolism during the fibrinolytic 
treatment. Fibrinolytic treatment would seem to be an 
attractive, nonsurgical alternative for the thrombosis of 
a valve prosthesis but, because of the risk of embolism 
with possible permanent damage, its use should be re•
served for critically ill patients who are too sick to undergo 
immediate surgery. 
(J Am Coil CardioI1986;7:743-51) 
be carried out. We tried fibrinolytic treatment in such pa•
tients and, after its initial success, extended its use. This 
report describes our findings in 26 patients who presented 
with 28 instances of thrombotic obstruction of a tilting disc 
or bileaftet valve. 
Methods 
Patients in the study (Table 1). Between June 1979 
and June 1984 more than 1,000 prosthetic cardiac valves 
were implanted at our hospital. A great number of the pa•
tients receiving these valves could not be retraced or died 
in unknown circumstances. In addition, three patients with 
prosthetic thrombosis, in whom fibrinolytic therapy was 
contraindicated, were treated surgically and are therefore 
not included in this report. During this period, we docu•
mented 28 massive acute thromboses, which cannot be rep•
resentative of all the complications that occurred. The 28 
prosthetic valve obstructions occurred in 26 patients, 17 
women and 9 men aged 17 to 81 years (mean 55.6), and 
involved 15 mitral prostheses (I with recurring thrombosis 
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Table 1. Summary of 28 Cases of Prosthetic Valve Thrombosis in 26 Patients* 
Age (yr) Delay Valve Findmgs on 
Case & Sex (mo) Prosthesis Clinical PresentatIOn Auscultation Echo CmeradlO. Treatment EvolutIOn -lr :I:m 
;:00 
55F 4 SJMMit APE, shock Abs. clicks, MR 4/6 UK FaIlure, surgery, died 0> 3:'2 
2 48M 3 SJM Ao Sub. APE, cardiac arrest Abs. clicks, AS 4/6 UK Success t:C m 
3 48M 3 + 19 SJM Ao. Sub. APE, AI 4/6, MR 3/6, + CmeanglOgram SK Succe", surgery ~-l 
2 cereb. embol. clicks + 6 months later c;;~ 0 
4 42M 6 SJM Ao. Leg embol. AI 3/6, muted clicks Cine angiogram UK Success 
'"r1 
0 
5 60M 2 BS Mil. APE, shock, VF Abs. clicks + + UK Succe", embol. c;; 
I"l 
6 60F 14 BSMit. Sub. APE, leg embol. Abs. clicks, MR 3/6 + + UK, SK Success, embol < 
7 60F 14 + 4 BS Mit. APE, leg embol. Abs. clicks, MR 3/6 + + SK Success, surgery > r 
8 72F 36 SJM Ao APE, BP 80/40 Abs. clicks ± SK, UK Success < m 
C/J 
9 55F 7 KO Mit. APE, leg embol. Click + MR 3/6 + Right cath. SK,UK Succe" 
\0 52F 15 BS Ao. APE, shock Abs. clicks, AI 3/6, ± + SK, UK Success, surgery 
AS 3/6 
II 69F 8 KOMit APE, shock Abs. clicks, MR 3/6 + SK Success, embol 
12 81M 9 KO Ao. Cereb. embol. Muted clicks, AI 2/6 0 + UK Success 
13 55F 18 BS MIt. APE, low Muted clicks + SK Improvement, 
output syndrome died 10th day 
14 71M 32 BS Ao. Sub. APE, shock Abs. clicks, AI 2/6, + + SK Success 
AS 4/6 
15 65F 33 BS Ao. Sub. APE. shock, Abs. clicks. AI 4/6, + + SK Succe" 
angmal pain AS 4/6 
16 76F 36 BS MIt. Sub. APE Abs. clicks. MR 3/6 + SK Succe" 
17 55F 4 KOMIt. Sub. APE. leg embol. Clicks + MR 2/6 ± ± UK Improvement. 
Right cath. died 7th day 
18 43F 22 BS Mit. APE. shock Abs. clicks. MR 3/6 + + SK. UK Succe". embol 
19 66M 96 BS Ao. APE. anginal pain Muted clicks. AI 2/6 ± SK Success 
20 55M 21 KOMa. APE. AF Abs. clicks + SK Success 
21 48F 132 BS Mit APE. AF Abs. clicks + UK. SK Improvement. surgery. 
died 
22 44M 15 BSMIt. Cereb. embol Clicks + MR 4/6 + + SK Success 
23 64F 84 BS Ao. APE. low Muted clicks. AI 3/6. ± SK Success 
output syndrome AS 3/6 
24 48F 33 BS Ao. APE Abs. clicks. AS 3/6 + + SK Success. embol. 
25 40F 60 BS Mit. APE. shock Abs. clicks. MR 3/6 + + SK. UK Success 
26 64F 48 SJM Ao Sub. APE. angmal pain Abs. clicks. AI 2/6. + SK Success 
AS 4/6 
27 17F 14 SJM MIt. APE. cardiac arrest Abs. clicks + + UK Failure. surgery 
28 42M 40 BSMa. APE. VT. shock Abs. clicks. MR 4/6 + + SK Success 
*Cases 2 and 3 involved Pallent 2 and Cases 6 and 7 involved Pallent 6. Abs = absent; AF = atnal fibrillation; AI aortic insuffiCiency murmur; Ao = aortic; 
» APE = acute pulmonary edema; AS = aortic stenosIs murmur; BP = blood pressure (mm Hg). BS = Bjork-Shiley. Cereb. = cerebral; CmeradiO. = cineradiography '0 I"l 
(+ = immobile or scarcely moving disc; ± = dlmimshed opening angle); Echo = echocardlOgram (+ = diagnostic of thrombosis; ± = doubtful: - = nondlagnostic; :l I"l 
=< o = uninterpretable); embol. = embolism; F = female; KO = Kaster-Omniscience valve; M = male. MIt. = mitral; MR = mitral regurgitatIOn murmur; Right cath ",0 ",,-
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4 months later) and 11 aortic prostheses (1 with recurring 
thrombosis 19 months later). The valve types were as fol•
lows: 15 Bjork-Shiley disc prostheses (9 mitral, 6 aortic), 
5 Kaster-Omniscience disc prostheses (4 mitral, 1 aortic) 
and 6 bileaflet St. Jude Medical prostheses (2 mitral, 4 
aortic). Excluding ball valve prostheses, the tilting disc and 
bileaflet valves are the only ones used by our team of sur•
geons. All 26 patients showed distinct improvement in their 
condition after valve replacement; postoperatively 14 were 
in New York Heart Association functional class I and 12 
were in class II. Thrombosis occurred between 2 months 
and 11 years after valve insertion: in 14 cases within 18 
months, in 8 cases between 18 and 36 months. and in 6 
cases after 3 years. At the time of valve thrombosis, in 18 
cases the patient was receiving no anticoagulant therapy or 
had an inadequate anticoagulant level; in the remaining 11 
cases the patient had effective warfarin therapy with optimal 
prothrombin times. 
Clinical features. The main clinical signs at the time of 
acute thrombosis of the prosthesis are summarized in Table 
1. In 15 cases the patient had acute pulmonary edema. low 
cardiac output and hypotension; cardiac arrest occurred in 
2 and ventricular fibrillation and tachycardia occurred in 2 
others. In 10 cases the patient had subacute clinical dete•
rioration, 5 presenting with congestive heart failure and 
peripheral or cerebral embolism and 3 presenting with sub•
acute pulmonary edema and severe dyspnea. In the three 
remaining cases the symptoms were systemic embolic ep•
isodes. The auscultatory findings were abnormal in all 28 
cases: absent prosthetic clicks with loud systolic or diastolic 
murmurs in 19, muted or intermittent closing clicks with 
the appearance of unusually loud murmurs in 5 and only 
prominent systolic murmurs in 4. Chest roentgenograms 
showed evidence of pulmonary edema in 25 cases with 
enlargement of heart size in 16. 
Diagnostic procedures. Complementary investigations 
(Table 2) confirmed the clinical indications of thrombosis 
of a prosthetic valve in all but the first two patients, who 
were in serious clinical condition. M-mode and two-di•
mensional echocardiograms were obtained with a Varian 
3000 or an RT 400 ultrasonoscope equipped with a 2.25 
MHz transducer. The patients were examined in the supine 
position. The echocardiographic examination was per•
formed in accordance with previously described standard 
techniques (7-9). In each patient various transducer angu-
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lations were attempted to obtain the maximal disc excursion. 
In 16 patients the tilting disc or the leaflets were radiopaque 
and allowed direct visualization of the disc motion by 
cineradiography. Following the technique described by Bjork 
et al. (10), the prosthesis was examined in two beam di•
rections: a beam direction corresponding to the axis of mo•
tion of the disc was found to calculate the maximal opening 
angle; a beam direction deviating 30 to 40° from the valve 
ring plane was used to study prosthetic valve closure. In 
four patients the diagnosis was not clearly confirmed by the 
preceding investigations and cardiac catheterization and an•
giocardiography were performed. 
Treatment. In all 28 cases of prosthetic thrombosis the 
patient was initially treated by fibrinolysis. The fibrinolytic 
agent was streptokinase (Streptase, Hoechst Laboratories, 
Germany) or urokinase (Urokinase, Choay Laboratories, 
France). In 14 cases streptokinase was infused in a periph•
eral vein with an infusion pump for 10 hours and 20 minutes 
(loading dose of 500,000 U in 20 minutes followed by 
1,500,000 U for 10 hours). In seven cases urokinase was 
infused under the same conditions for 12 hours at a constant 
dose (4,500 U/kg per h) without a loading dose. In seven 
cases, the first fibrinolytic agent used (streptokinase in five 
cases and urokinase in two) was insufficient and the other 
fibrinolytic agent was infused at the same dose 24 or 48 
hours later. In all cases the choice of treatment was arbitrary. 
Urokinase and streptokinase were administered in the doses 
usually recommended in cases of pulmonary embolism (11). 
Heparin infusion was introduced after the fibrinolytic 
treatment, when the fibrinogen level was higher than 0.5 
g/liter; this was usually 6 to 18 hours after the end of the 
fibrinolytic treatment. Heparin infusion to obtain a thrombin 
time at least twice the control value was continued for 7 to 
10 days, then replaced by warfarin treatment adjusted to 
obtain optimal prothrombin times. 
Blood coagulation tests were performed before fibrino•
lytic treatment, at the end of treatment, 6 and 12 hours later 
and then daily. They included measurement of prothrombin 
time, cephalin-kaolin time, determination of fibrinogen by 
the chronomatic method of Van Clauss (2), detection of 
fibrin/fibrinogen degradation products by means of latex 
particles coated with a new antibody (13) and determination 
of plasminogen level by chronometric method on chromo•
genic substrate (14). 
Evaluation of the results of treatment was based on clin•
ical and auscultatory findings and echocardiographic and 
cineradiographic studies. When necessary. right or left heart 
catheterization, or both, and cinecardiography were per•
formed after treatment. 
Results 
Clinical results (Table 3). In 28 instances of acute 
thrombosis of a prosthetic heart valve in 26 patients, fi•
brinolytic therapy was administered. The treatment was im-
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Table 3. Clinical Results of Fibrinolytic Therapy in 28 Instances of Prosthetic Valve 
Thrombosis In 26 Patients 
Results of Fibrinolytic Therapy Subsequent Treatment Patient Outcome 
Success 23 
[
Medical treatment: 18 
Surgical revision: 3 
-Alive 18 (69.2%) 
-Alive 3 (11.5%) 
Improvement 3 
[
Medical treatment: 2 
Surgery: 1 
-Died 2 (11.5%) 
-Died 
Failure 2 - Surgery: 2 
[
Alive 1 (7.7%) 
Died 
mediately «24 hours) and entirely successful in 23 in•
stances of thrombosis in 21 patients (thrombosis recurred 
in 2 patients who were again successfully treated by fibri•
nolysis). In these 21 patients, congestive heart failure, shock 
and arrhythmias disappeared. The prosthetic closing clicks 
reappeared suddenly and loud murmurs subsided. After a 
follow-up period of 6 to 64 months (mean 36.5 ± 16), 18 
of the 21 are well and in functional class I or II, free of 
new embolic episodes with anticoagulant therapy. Three 
patients were later reoperated on: two for persisting echo•
cardiographic or cineradiographic abnormalities (residual 
thrombus was found on the prosthetic ring during surgery: 
thrombectomy in one patient and replacement with a xeno•
graft valve in one ); the third patient underwent surgery after 
two successfully treated thromboses (the operation showed 
that the valve was, in fact, quite normal and free and it was 
left in place). 
In three patients, there was incomplete clinical improve•
ment: congestive heart failure disappeared slowly, but c1os-
Before SK After SK 
ing clicks reappeared. Surgery was under consideration for 
two of these patients when they died suddenly from a new 
massive thrombosis on the 7th and 10th day, respectively, 
after treatment. The third patient was reoperated on 3 days 
after fibrinolysis, but died soon afterward from intractable 
hypotension despite insertion of a xenograft valve. Fibrin•
olytic treatment failed completely in two patients who suf•
fered from persistent cardiogenic shock and pulmonary edema, 
leading to surgery I day after fibrinolysis. In these two 
patients a St. Jude Medical valve was replaced by a xen•
ograft valve; one of these patients survived, the other died. 
Complications of fibrinolytic treatment. We did not 
observe any hemorrhagic complications; there was no bleed•
ing or neurologic hematoma even in the patients with tran•
sient neurologic signs of cerebral embolism in the days 
preceding fibrinolytic treatment. In contrast, arterial throm•
boembolic complications occurred during treatment in five 
cases (cerebral embolism in two and peripheral embolism 
in the left arm and the legs in three). All symptoms were 
Op speed ,224 mmls Op speed 52Omm,.. 
Clos speed . 280 mmls (A) 
i . i , 
Clos. speed 760mm/$ . B 
I I I . -
Figure 1. M-mode echocardiogram of a throm•
bosed Bjork-Shiley prosthetic valve in the mitral 
position. A, Before streptokinase (SK) therapy. 
There are dense echoes at the site of the pros•
thesis, with rounded angles; the disc is not quite 
clear, with diminished opening (Op.) and clos•
ing (Clos.) rates. After fibrinolysis (B), the 
echocardiographic pattern is quite normal, with 
normal opening and closing rates. 
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transient and subsided a few hours to 2 days later with 
medical treatment except in one patient with leg embolism 
who was surgically treated. We think that these emboli were 
linked to the breaking up of the clot situated near the pros•
thetic heart valve. 
Hemodynamic results. Right heart catheterization was 
performed with a Swan-Ganz catheter in five patients, four 
with prosthetic mitral thrombosis and one patient with pros•
thetic aortic thrombosis. In four patients, we observed good 
improvement: pulmonary artery systolic pressure decreased 
from 62.7 ± 19 to 39.5 ± 13 mm Hg (p < 0.02), pul•
monary artery diastolic pressure fell from 29.1 ± 11 to 
15.2 ± 4 mm Hg (p < 0.01) and cardiac index rose from 
0.8 ± 0.4 to 0.95 ± 0.2 liters/min per m2 (p < 0.01). In 
the fifth patient, pulmonary pressures diminished slightly 
and the cardiac index stabilized at 1.4 liters/min per m2; 
emergency operation was performed. 
Echocardiographic results. An echocardiogram was 
performed in 15 patients with a mitral prosthetic valve. In 
13, the patterns suggested thrombosis of the valve (Fig. 1) 
with diminished amplitude of excursion, marked reduction 
of both the opening (24 to 184 mmls) and closing (90 to 
380 mmls) rate of the disc and blunting of upstroke and 
downstroke. In two, the echocardiographic features were 
doubtful or did not suggest a thrombotic obstruction. After 
fibrinolytic treatment, all abnormal features disappeared in 
11 of the 15 patients: opening rate increased from 144 ± 
Figure 2. Evolution of opening and closing rates, before and after 
fibrinolysis, of the disc valve prostheses in the mitral position in 
14 cases. The patients who died from recurrent thrombosis or after 
surgery had apparently normal opening and closing rates. One 
patient with a St. Jude Medical valve in the mitral position is not 
presented in the figure. 
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Figure 3. M-mode echocardiogram of a thrombosed Bjork-Shiley 
prosthesis in the aortic position. Before streptokinase (SK) treat•
ment (top), the aortic (Ao) root echocardiogram (left) is filled with 
dense, thick echoes; no disc is visible. There is fine fluttering of 
the anterior leaflet of the mitral valve (right). After fibrinolysis 
(bottom), all signs of dysfunction disappeared; there is no mitral 
fluttering. IVS = interventricular septum; LA = left atrium; 
LV = left ventricle: PW = posterior wall; RV = right ventricle. 
188 to 487 ± 175 mmls (p < 0.(01) and closing rate 
increased from 224 ± 105 to 753 ± 293 mrn/s (p < O.OOl) 
(Fig. 2), disc excursion became normal and upstroke and 
downstroke were sharp. Eight thrombi around the prosthetic 
valve in the left atrium, evident on two-dimensional views, 
totally disappeared after treatment. In four patients abnormal 
valve features persisted with diminished opening and closing 
rates or intermittent reduction of disc excursion or blunt 
angles. One of these patients was operated on with success 
and the three others died a few days later without or despite 
surgery. 
An echo cardiogram was performed in 10 patients with 
an aortic prosthetic valve. In only four patients was echo•
cardiographic evidence of thrombosis obtained that included 
absence of disc motion, filling of the aortic root with dense, 
thick echoes and fluttering of the mitral valve (Fig. 3). In 
four patients the echocardiographic pattern was doubtful and 
could not be used to determine the diagnosis even on two•
dimensional views. Two echocardiograms allowed no di•
agnosis of thrombosis (one St. Jude Medical valve seemed 
normal and there was one unsatisfactory recording). Fi•
brinolytic treatment normalized the eight abnormal or doubt•
ful echocardiographic patterns; after treatment, the record•
ing showed a clearly moving disc in the aortic lumen and 
a normal mitral valve. 
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Cineradiographic studies. In 16 patients the tilting disc 
or the leaflets were radiopaque. The diagnosis of thrombosis 
was simply and instantaneously confirmed in 11 patients in 
whom the disc was immobile, fixed in an intermediate po•
sition (Fig. 4) or had an angle of motion less than 15°. In 
three patients the opening angle was 20 or 30°, in one patient 
the opening angle was 50° but closure was incomplete and 
in one patient the opening angle was 40°. After treatment 
the opening angle became normal (>45°) in 13 patients (Fig. 
5). In one patient the opening angle remained unchanged 
at 40° and death occurred 7 days later. 
Angiocardiographic studies. Aortography was per•
formed in two patients with a nonradiopaque St. Jude Med•
ical valve in the aortic position. The cineangiograms showed 
severe aortic insufficiency and one leaflet remained fixed 
but these findings disappeared after fibrinolytic treatment. 
In two patients with a mitral Kaster-Omniscience nonradio•
paque disc valve, cineangiograms revealed a marked delay 
of left atrial emptying, filling defects around the prosthesis 
and an immobile disc. Reexamination after treatment con•
firmed normal disc motion and absence of thrombus in one 
of these patients. 
Figure 4. Cineradiographic examination, at a rate of 25 expo•
sures/s, of a tilting disc Bjork-Shiley prosthesis in the mitral po•
sition. The beam direction corresponds to the axis of motion of 
the tilting disc. A, On admission, the radiopaque marker is im•
mobile in the intermediate position. B, After fibrinolytic treatment, 
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Fibrinolytic findings. In seven cases the patient re•
ceived urokinase and streptokinase treatment successively. 
Therefore, 35 fibrinolytic treatments were administered (14 
urokinase and 21 streptokinase). The fibrinogen levels de•
creased with both streptokinase ( - 78 ± 2%) and urokinase 
(-33 ± 18%) (p < 0.01). The plasminogen levels de•
creased with streptokinase from 90.4 ± II to 8.8 ± 6% 
and with urokinase from 88.8 ± 9 to 44.3 ± 21 % (p < 
0.001). The mean level of fibrin/fibrinogen degradation 
products was 61.8 ± 26 jLg/ml after urokinase and 
345.5 ± 410 jLg/ml after streptokinase (p < 0.05). How•
ever, there was no correlation between the clinical course 
and the biologic results. In five cases of treatment failure 
or incomplete improvement, fibrinogen level decreased be•
low 0.80 g/liter in three and was unchanged in two. On the 
other hand, among the 23 clinical successes, the fibrinogen 
and plasminogen levels remained unchanged, or fibrinogen 
was higher than 1.50 g/liter in 8 cases. Finally, we observed 
no difference between urokinase and streptokinase treat•
ment: there were 14 urokinase treatments with 8 successes 
(64%) and 21 streptokinase treatments with 14 successes 
(66%). 
Discussion 
Thromboembolic complications are a permanent risk with 
prosthetic cardiac valves, despite anticoagulant therapy and 
improvements in valve design. The most severe form is 
thrombosis of the prosthesis itself. The incidence of late 
11&& L 
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Figure 5. Evolution of opening angle of radiopaque tilting disc 
valves before and after fibrinolysis in 14 cases, One patient had 
the same angles and died. The patient with incomplete (Incompl.) 
closure was operated on. The two with a radiopaque bileaftet St. 
lude Medical valve are not presented. 
arterial thromboembolic complications appears to be the 
same with disc valve and ball valve prostheses (l). Only 
disc valves were involved in our study, which are the only 
type of valve inserted by our surgeons for hemodynamic 
reasons and because of their slight degree of hemolysis. 
Predisposing factors. Many factors other than valve de•
sign affect thromboemboiic complications. Long-term an•
ticoagulant therapy is the most important (15-17). In our 
study 17 patients had no effective anticoagulant treatment. 
Anticoagulant therapy was not used in 4 of the 17 patients 
after St. Jude Medical valve insertion because of our initial 
policy, in 6 patients it was discontinued for medical reasons 
or by the patients themselves and in 7 patients receiving 
warfarin derivative treatment, control of prothrombin time 
was inefficient. Eleven patients had effective anticoagulant 
treatment at the time of thrombotic obstruction, but seven 
of them had had repeated normal or suboptimal prothrombin 
time at routine follow-up visits during tlie preceding months. 
Atrial fibrillation (13 cases in our study) also increases 
the risk of thrombosis. Enlargement of the left atrium (two 
cases in but study) and previous valve infection (two cases) 
are additional risk factors. 
Clinical features. The clinical characteristics of tlirom•
bosis of prosthetic valves have been clearly defined by other 
investigators (3,18,19). In most cases the clinical deterio•
ration is acute and quickly becomes life-threatening. How•
ever, in some patients signs of congestive heart failure and 
chest pain appear progressively a few weeks before the 
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thrombotic dramatic accident. Five patients in our study had 
intermittent dyspnea or dizziness 2 months before hospital 
admission. Therefore, minimal symptoms in patients whose 
condition was good after valve replacement require careful 
investigation. 
Diagnostic considerations. Echocardiographic study 
appears to be of considerable value in the diagnosis of tilting 
disc and leaflet valve thrombosis in the mitral position (9,20), 
where recording is not difficult and can be reproduced. In 
the case of massive thrombosis, the echocardiographic pat•
tern is quite evident and diagnosis can be determined. With 
partial thrombosis, diagnosis is more difficult and compar•
ison with a previous baseline echocardiogram is important. 
Time must be taken to identify intermittent reduction of disc 
motion or blunt angles and to evaluate reduction in opening 
and closing rates compared with rates in the postoperative 
baseline echocardiogram, Echocardiographic study of a 
prosthetic valve in the aortic position is more difficult and 
often unusable for diagnosis for technical reasons, despite 
use of the suprasternal and supraclavicular approach which 
may provide interesting information. With the St. Jude Med•
ical valve in the aortic position, an echocardiogram may 
appear normal when only one mobile part of the valve is 
fixed. Thus, cardiac catheterization should be performed in 
patients in whom thrombosis is clinically suspected and a 
nondiagnostic echocardiogram should also be obtained (21). 
Echocardiograms are also valuable in the assessment of the 
efficacy of fibrinolytic treatment. After treatment, the echo•
cardiographic pattern of the prosthetic valve should become 
quite normal, similar to a postoperative one, with normal 
opening rate, closing rate and disc motion. All persisting ab•
normal features must lead to angiographic study and surgery. 
When the disc or the leaflets of the valve are radiopaque, 
cineradiography is the first examination to be used for di•
agnosis. This method is simple and well tolerated by all 
patients, even when critically ill. The opening angles are 
not the same for different prosthetic valve types and depend 
on the trans valvular flow. Marked left ventricular failure 
may diminish the opening angle. Also, only a very reduced 
opening angle, far below that of the normal value (60° for 
Bjork-Shiley, 80° for Kaster-Omniscience and 90° for St. 
Jude Medical valves), associated or not with incomplete 
closure, confirms the diagnosis of thrombosis. The feature 
most often observed is a disc fixed in an intermediate po•
sition or barely moving around this intermediate position. 
In our experience, cineradiography affirmed the diagnosis 
in 15 of 16 examinations. When thrombosis of a prosthetic 
valve is clinically suspected, cineradiography should be the 
first examination because of the absence of risk and its 
rapidity and sensitivity. This study is also valuable in the 
assessment of fibrinolytic treatment; it can accurately eval•
uate the extent to which the prosthesis has been cleared after 
treatment. Persistent reduction of an opening angle requires 
cardiac catheterization and surgery without delay. 
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Among patients in poor clinical condition with abnormal 
prosthetic sounds. the echocardiogram or cineradiogram, or 
both, always confirmed the diagnosis of thrombosis in our 
study. An angiographic examination was necessary in only 
four patients who were in relatively good condition with 
minimal symptoms but who were suspected of having pros•
thetic thrombosis. 
Therapeutic considerations. Massive thrombosis of a 
prosthetic cardiac valve is always a life-threatening event. 
In three published studies (3,5,16), the mortality rate was 
between 33 and 60.2% before or after reoperation. Simple 
thrombectomy on an aortic valve prosthesis seemed to give 
better results, with five successes in eight cases for Bjork 
and Henze (22) and seven consecutive successes for Ayuso 
et al. (5). However, nonsurgical treatment is an attractive 
alternative, especially for very sick patients. 
In the first patients to be treated with fibrinolysis for 
acute thrombotic obstruction of a prosthetic cardiac valve, 
reported in 1971 and 1977, the tricuspid valve was involved 
(23,24). In 1980, Witchitz et al. (25) reported on fibrinolytic 
treatment in 13 consecutive cases of thrombosis at mitral 
and aortic valves with a 70% success rate. Our study began 
in 1979 and includes 28 cases (26 patients). Fibrinolysis, 
without surgery, was entirely successful in 18 of these cases. 
The patients were followed up for 6 to 64 months without 
recurring thromboembolic accidents. These findings dem•
onstrate that surgical intervention is not necessary after ef•
fective thrombolytic treatment. All of these patients receive 
permanent adequate anticoagulant therapy. In two other pa•
tients, all clinical and echocardiographic signs of valve dys•
function disappeared with fibrinolysis, but thrombosis re•
curred 4 and 19 months later, respectively, when anticoagulant 
therapy was ineffective. The recurrence probably repre•
sented a new thrombotic obstruction rather than residual 
thrombus after the first treatment. In one patient, surgical 
revision after a second fibrinolytic treatment proved unnec•
essary and the prosthetic valve was left in place. The final 
success rate was 21 (75%) of 28 cases. 
In our study the fibrinolytic treatment took effect quickly 
(within 12 to 24 hours), with closing valve clicks reap•
pearing suddenly. After that interval, absence of improve•
ment or persistent signs of dysfunction require reoperation, 
which can be performed a few hours after fibrinolytic ac•
tivity has been neutralized by protease inhibitors and fresh 
plasma. Two operations were performed in such circum•
stances without hemorrhagic complications: one patient sur•
vived and the other patient died of left ventricular failure 
on the third day after the operation. 
The choice of either urokinase or streptokinase fibrino•
lytic treatment was arbitrary and both agents were equally 
effective. In seven cases, the first treatment was only par•
tially successful and persistent signs of dysfunction required 
a second treatment with the other drug 2 to 3 days later. It 
is possible that a longer initial period of treatment with the 
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first drug, over 24 or 36 hours, would give the same results. 
In the other reported experiments, the dosage of drugs and 
times of infusion are variable and no conclusions can be 
reached. With our treatment, no hemorrhagic complications 
were observed and, in any event, these are not common. 
The major risk is embolism from thrombolysis of the valve 
thrombus. This complication is infrequent: 2 instances in 
the 13 patients of Witchitz et aI. (25) and 5 in 28 cases in 
our study. All the patients recovered with medication (fi•
brinolysis) or surgical treatment (femoral embolism extrac•
tion). Nevertheless, because small emboli could easily result 
in permanent brain damage such as hemiplegia we do not 
recommend the systematic use of fibrinolysis in all cases of 
thrombosis of prosthetic heart valves, but believe it should 
be reserved for critically ill patients who are too sick to 
undergo immediate surgery. 
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